KDM2B and synovial sarcoma: A similar phenomenon was clear from ChIP-Seq for KDM2B in mouse synovial sarcomas after treatment with vehicle or decitabine or 5-AZA, with a diminution of ChIP-Seq enrichment at the promoters of known fusion target genes.